PCI Pharma Services' multi-million-dollar expansion to UK oncology manufacturing facility

Global contract development and manufacturing organization (CDMO) PCI Pharma Services (PCI) today announced a significant expansion of its world-class facility in Tredegar, Wales, UK, designed to help keep pace with the market growth of powerful, targeted oncology therapies.

“We’re excited to announce the latest expansion in Tredegar that will address the growing and urgent need for specialty global manufacturing services within the oncology arena,” said Salim Haffar, chief executive of PCI Pharma Services. “As the market expands for potent therapies and highly complex, concentrated formulations that can present unique challenges to manufacturing and packaging, we’re proud to be one of the few providers with the global capabilities to manage this specialty at both clinical and importantly, commercial scale,” he added.

The expansion includes two new facilities dedicated to the manufacturing and packaging of solid oral-dose tablets and capsules. A second contained manufacturing building (CMF2), capitalizing on the success of the original CMF1 which opened in 2013, will double large-scale processing capacity including dispensing and fluid bed granulation of high-potency solid-dose products at the commercial scale. In addition, there is a new high-potency, multi-product packaging facility with primary and secondary blistering and bottling suites. The primary and secondary packaging lines provide a fully integrated process, delivering end-to-end services for a global client base.